Pfizer and BioNTech said that updated data from a Phase 2-3 clinical trial shows the bivalent booster performed better against the BA.4 and BA.5 omicron subvariants.
Source: Test feed
Pfizer, BioNTech say bivalent booster performs better against BA.5 omicron subvariant
11/04/2022 | Uncategorized
